Gene Therapy Market Research Report - Forecast till 2030

Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo), Indication (Oncology, Genetic Diseases) and End-User (Hospitals & Clinics, Specialty Treatment Centers) - Forecast to 2030

ID: MRFR/HC/6927-HCR | January 2023 | Region: Global | 111 Pages         

Gene Therapy Market Speak to Analyst Request a Free Sample

Gene Therapy Market

Gene Therapy Market is expected to reach USD 3,251.92 million at CAGR of 19.10% by 2022 - 2030

By Product Kymriah Luxturna Yescarta Zolgensma Strimvelis Zynteglo
By Indication Oncology Genetic Diseases
By End User Hospitals & Clinics Specialty Treatment Centers
Key Players
Companies Profiled   Amgen Inc. (US)   Spark Therapeutics Inc. (US)   Bristol-Myers Squibb Company (US)   Novartis AG (Switzerland)   Gilead Sciences Inc. (US)   Celgene Corporation (US)   Thermo Fisher Scientific Inc. (US)   CEVEC (Germany)   uniQure N.V. (Netherlands)   Orchard Therapeutics plc (UK)
Market Driving Forces   Robust product pipeline   Increasing investment by key players   High prevalence of target diseases and demand for innovative medication
Request a Free Sample

Gene Therapy Market Overview

The Gene Therapy Market is expected to reach USD 3,251.92 million by 2030 at 19.10% CAGR during the forecast period 2022-2030.

A gene, a functional hereditary unit of life, carries an instruction set for a particular function. Gene therapy is the most cutting-edge treatment for blood problems, chronic illnesses, infectious diseases, and cancer. To cure or stop the spread of disease, gene therapy entails replacing some or all of a patient's body's damaged genes with healthy ones. Based on where the target gene is located on a chromosome, there are two different forms of gene therapy: somatic gene therapy and germline gene therapy.

Globally rising rates of cancer, uncommon diseases, genetic abnormalities, and other chronic diseases are the main factors fuelling the growth of the gene therapy market. The market is expanding due to rising government backing, ethical acceptance of gene therapy as a cancer treatment, and an increase in cancer occurrence. Additionally, there is a market opportunity for gene therapy due to rising healthcare costs, cutting-edge healthcare infrastructure, and the availability of reimbursements. However, gene treatment costs are anticipated to somewhat restrain market expansion throughout the forecast period.

Technology advances increased research and development spending, and the rising frequency of target illnesses are the main drivers of the market's expansion. Research and development spending is anticipated to significantly impact the industry.

Covid-19 Analysis

The utilization of hereditary Gene was a focal apparatus in understanding the impact of a few sicknesses, even the COVID-19 contamination. The component of exactness in Gene Therapy is assessed to set out more open doors for the market as it tends to be sent adequately to treat sicknesses that don't have any therapy yet. Gene Therapy is accessible to convey a viable therapy decision for patients that have progressed protection from chemotherapies across various malignancy signs. The spread of covid-19 has impacted the Gene Therapy market to a great extent. There is a high demand for Gene Therapy due to the covid-19 situation, which ultimately enhances the market's growth. 

Market Dynamics


The market for Gene Therapy is assessed to be reinforced by a vigorous item pipeline. The developing financing by key players is anticipated to make positive scenery for improvement in the coming years. Likewise, the raised event of target infections and creative medicine necessities is expected to prod the Gene Therapy Industry for the forecasted market.


The different components driving the market of Gene Therapy, incorporate the rising occurrence of malignancy and different sicknesses, developing a quality treatment pipeline and expanding subsidizing for the Gene Therapy research. But the significant expense related to Gene Therapy and not many repayment options is considered as a challenging factor in the Gene Therapy market. Hence this challenge must be effectively dealt with in order to enhance the growth of the Gene Therapy Industry. 


An increment in subsidizing and venture for progressions in quality treatments are required to give rewarding development freedoms to the key players. It is considered an effective opportunity that is driving the market growth of the Gene Therapy. Moreover, organizations are occupied with key unions to support their contributions in the space, which is expected to heighten the market rivalry during the estimated time frame.


The Gene Therapy market is evaluated to be limited because of the raised expense of item improvement for a few treatments. Besides, the thorough administrative approaches are anticipated to additionally decrease the development of the Gene Therapy Industry in the estimated time frame.

Cumulative growth Analysis

The extending field of cutting-edge treatments and Gene conveyance advances has made an undeniably aggressive powerful where a considerable number of market players are occupied with the commercialization of their Gene Therapy items. Treatment designers put resources into the joint effort and secure bargains as a suitable system to improve in-house aptitude and fortify item pipelines. These elements are required to help the market development of Gene Therapy. Besides the high costs of presently accessible treatments, the market growth of Gene Therapyis boosted. But the lack of Gene Therapy availability can bring down the Gene Therapy Industry growth because of the absence of monetary suitability of the items.

Segment Overview

  • By Product

Based on product, the Gene Therapy market is portioned into Strimvelis, Kymriah, Luxturna, Imlygic, Yescarta, Zolgensma, Zynteglo, and much more. Kymriah and Luxturna are the principal endorsed Gene Therapy and, in this manner, hold a significant offer in the Gene Therapy Industry. Kymriah is utilized to treat intense lymphoblastic lymphoma, while Luxturna is utilized to treat retinal dystrophy. Imlygic is the first oncolytic viral treatment. 

  • By Indication

Based on indications, the Gene Therapy Industry is divided into oncology, hereditary illnesses, and much more. The hereditary infections section holds the biggest offer in the market of Gene Therapy. At the same time, the oncology fragment is required to develop at the most elevated rate over the estimated time frame. 

  • By End-user

Based on end-use, the worldwide quality treatment market is portioned into forte treatment habitats, clinics and facilities, and much more. Medical clinics and facilities contain the biggest portion of the Gene Therapy market.

Regional Analysis 

The Gene Therapy market has been partitioned, based on region, into the Asia-Pacific, Americas, Europe, and the Middle East, and Africa. The Americas must be the biggest market attributable to the expanding pervasiveness of quality treatment and rising per capita medical care consumption. The Gene Therapy Industry in the Americas has additionally been fanned into North America and Latin America, with the North American market separated into the US and Canada. The European quality treatment market has been sorted as Western Europe and Eastern Europe. The Western European market has also been delegated to Germany, France, the UK, Italy, Spain, and Western Europe. The Gene Therapy market in Asia-Pacific market of has been portioned into Japan, China, India, South Korea, Australia, and the remainder of Asia-Pacific. Because of the expanding number of patients and bringing issues to light about the treatment strategies, the market in Asia-Pacific is relied upon to be the quickest developing. The Gene Therapy Industry in the Middle East and Africa has been separated into the Middle East and Africa.

Major Market Players

The key players of the Gene Therapy market

  • Amgen, Inc. (US)

  • Spark Therapeutics, Inc. (US)

  • Bristol-Myers Squibb Company (US)

  • Novartis AG (Switzerland)

  • Gilead Sciences, Inc. (US)

  • Celgene Corporation (US)

  • Thermo Fisher Scientific Inc. (US)

  • CEVEC (Germany)

  • uniQure N.V. (Netherlands)

  • Orchard Therapeutics plc (UK)

  • Lonza (Switzerland)

Recent Developments

  • The United States has had a sizable portion of the market in North America. The main drivers of market growth are the government's expanding funding, developments in gene therapy research and development, and the rising incidence of target illnesses.

  • Several businesses are working to develop a gene therapy platform with a strategy that focuses on developing an innovative portfolio using internal resources and enhancing those resources through strategic partnerships, increased research and development, as well as potential licencing, merger, and acquisition activities.

Report Overview

  • Market overview highlights the global recognition of¬†Gene Therapy Market Analysis¬†overview

  • Analysis based upon COVID 19

  • Explanation upon the Market Dynamics

  • Value chain analysis for the market Share¬†Report.

  • Market segmentation overview

  • The regional analysis of¬†Market Trends¬†overview

  • Competitive landscape analysis

  • Recent Developments of¬†Market Forecast

The report highlights the Gene Therapy Market Growth development includes its revenue hike's growth potential by the end of the forecast years in 2030.

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 3,251.92 Million
  CAGR   19.10%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Indication, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen, Inc. (US), Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), uniQure N.V. (Netherlands), Orchard Therapeutics plc (UK), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), CEVEC (Germany), Lonza (Switzerland)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Robust product pipeline
  • Increasing investment by key players
  • High prevalence of target diseases and demand for innovative medication

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Based on product, Gene therapy industry divided into kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo, imlygic, and others. Kymriah: Novartis AG reported an annual sale of USD 3,251.92 million in 2030. Zynteglo: The drug indicated for transfusion-dependent ő≤ thalassaemia (TDT), is the second most expensive drug valued at an approximate value of USD 1.8 million. Yescarta: The drug was approved by the US Food and Drug Administration (FDA), in 2030, for the treatment of B-cell lymphoma.

    Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), uniQure N.V. (Netherlands), Gilead Sciences, Inc. (US), Orchard Therapeutics plc (UK), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), and CEVEC (Germany), are some of the major players operating in the gene therapy market.

    The gene therapy market had reached a valuation of USD 3,251.92 million in 2030.

    The gene therapy market is projected to grow at approximately 19.10% CAGR during forecast period (2022-2030).

    Rising technological advances and favorable government initiatives.

    North America holds the largest share in the gene therapy market, followed by Europe and the Asia Pacific, respectively.

    The key players are investing in the manufacturing of cell and gene therapy treatments due to its target specificity. In the regional market Asia-Pacific is expected to be the fastest-growing market. On the basis of Indication The oncology segment is expected to hold the largest market share and to be the fastest-growing segment due to high prevalence of cancer and robust pipeline for cancer gene therapy.